The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EMITT-1: Clinical and pharmacodynamic activity with the oral ERAP1 inhibitor GRWD5769 and cemiplimab in 6 completed phase 1b expansion cohorts in solid tumors with anti–PD-1 resistance or MSS-CRC.
 
Fiona Thistlethwaite
Consulting or Advisory Role - AstraZeneca; Grey Wolf Therapeutics; Immatics; Oncobayes (Inst); T-Knife; Waypoint Bio
Research Funding - Achilles Therapeutics (Inst); Adaptimmune (Inst); Amgen (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Corbus Pharmaceuticals (Inst); Crescendo Bioscience (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Grey Wolf Therapeutics (Inst); Immunocore (Inst); Incyte (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Kymab (Inst); Leucid Bio (Inst); Moderna Therapeutics (Inst); NovalGen (Inst); Nucana (Inst); Oxford VacMedix (Inst); Roche (Inst); RS Oncology (Inst); Sanofi (Inst); Seagen (Inst); T-Knife (Inst); Takeda (Inst); UCB (Inst); Zymeworks (Inst)
 
Desamparados Roda
Consulting or Advisory Role - Abbvie
Travel, Accommodations, Expenses - SERVIER
 
Eduardo Castanon Alvarez
Honoraria - Bms spain; Gilead Sciences; GlaxoSmithKline; GlaxoSmithKline; MSD Oncology; Pfizer; Pfizer; Roche
Consulting or Advisory Role - BeiGene; MSD Oncology
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bms Spain; MSD; Roche; Roche
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Abbvie; Affimed Therapeutics; AstraZeneca; Basilea; Bayer; BMS; Ellipses Pharma; Janssen Oncology; Merck; Roche
Speakers' Bureau - Bayer; Pierre Fabre
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); ADC Therapeutics (Inst); Amgen (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); Biomea Fusion (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Crescendo Bioscience (Inst); Cullinan Oncology (Inst); E-therapeutics (Inst); Eisai (Inst); F-Star Biotechnology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Grey Wolf Therapeutics (Inst); hemavant (Inst); HiFiBiO Therapeutics (Inst); Janssen (Inst); Kinnate Biopharma (Inst); Menarini (Inst); Merck (Inst); MonTa Biosciences (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Revolution Medicines (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
Other Relationship - BMS
 
Tatiana Hernandez Guerrero
No Relationships to Disclose
 
Javier García-Corbacho
Research Funding - Multiple sponsors (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Jia Liu
Honoraria - Merck; MSD; Taiho Oncology
Consulting or Advisory Role - Greywolf Therapeutics; Starpharma (Inst)
Research Funding - Abbvie (Inst); ALX Oncology (Inst); AVEO (Inst); AVEO (Inst); Bayer (Inst); BeOne (Inst); Bristol Ms Squibb (Inst); Bristol-Myers Squibb (Inst); Carina Biotech (Inst); Covus therapeutics (Inst); Daiichi Sankyo/UCB Japan (Inst); Greywolf Therapeutics (Inst); Guardant Health (Inst); IDEAYA Biosciences (Inst); ImmVirX (Inst); Innovent Biologics (Inst); MediLink Therapeutics (Inst); Merus (Inst); MSD (Inst); Nested Therapeutics (Inst); OncoNano Inc (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Starpharma (Inst)
Travel, Accommodations, Expenses - Innovent Biologics; Starpharma
 
Vikram Jain
No Relationships to Disclose
 
Emiliano Calvo
Employment - HM Hospitales; START
Leadership - BeiGene; CHUV; European Organisation for Research and Treatment of Cancer (EORTC); Oncomatryx; PharmaMar; Sanofi; Shionogi; START
Stock and Other Ownership Interests - HM Hospitales; Oncoart Associated; START
Consulting or Advisory Role - Abbvie; Anaveon; Aromics; AstraZeneca/MedImmune; Chugai Pharma; Column Group; Debiopharm Group; Ellipses Pharma; Genmab; Grey Wolf Therapeutics; Incyte; Janssen-Cilag; Kivu; Medsir; MonTa Biosciences; Roche/Genentech; Servier; TargImmune Therapeutics; Weber Spain
Research Funding - START
Other Relationship - CRIS Cancer Foundation; Foundation PharmaMar; Investigational Therapeutics in Oncological Sciences
 
Iphigenie Korakis
Honoraria - MSD; Pierre Fabre
Research Funding - Abbvie (Inst); Amgen (Inst); Anaveon (Inst); Astellas Pharma (Inst); C4 Therapeutics (Inst); DAIICHI Sankyo (Inst); Dragonfly Therapeutics (Inst); Fore Biotherapeutics (Inst); Grey Wolf Therapeutics (Inst); ImCheck therapeutics (Inst); Immunocore (Inst); Merck (Inst)
 
Kaïssa Ouali
Consulting or Advisory Role - Amgen; Anaveon; Sotio
Travel, Accommodations, Expenses - Amgen; Eisai; Sotio
 
Thibault De La Motte Rouge
Honoraria - AstraZeneca; Gilead Sciences; GlaxoSmithKline; MSD Oncology; Mylan; Pfizer; Roche/Genentech; Sanofi; Tesaro
Consulting or Advisory Role - Abbvie; AstraZeneca; Eisai; Eisai; Gilead Sciences; GlaxoSmithKline; MSD Oncology (Inst); Mylan; Pfizer; Regeneron; Roche; Sanofi; Tesaro
Research Funding - AstraZeneca (Inst); Novartis (Inst); Pfizer (Inst); seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Eisai; Gilead Sciences; MSD; Pfizer; Roche
 
Ruth Plummer
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Novartis Pharmaceuticals UK Ltd.; Sanofi/Aventis
Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Benevolent AI; Biosceptre; Bristol-Myers Squibb/Medarex; CV6 Therapeutics; Cybrexa Therapeutics; Ellipses Pharma; Genmab; Immunocore; Incyte; Nerviano Medical Sciences; Novartis; Novartis
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology
Other Relationship - Alligator Bioscience; AstraZeneca; GlaxoSmithKline; PharmaMar; Sotio
 
Christian Ottensmeier
Stock and Other Ownership Interests - NEUVOGEN
Honoraria - Delcath Systems; Transgene
Consulting or Advisory Role - Bristol-Myers Squibb; Delcath Systems; Merck Sharp & Dohme; NEUVOGEN
Speakers' Bureau - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme; Roche
Research Funding - BioNTech (Inst); Bristol-Myers Squibb (Inst); Delcath Systems (Inst); Merck Sharp & Dohme (Inst); PsiOxus Therapeutics (Inst); Scancell (Inst); Touchlight Genetics (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - patents on modulation of T cell function
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Delcath Systems
Other Relationship - Transgene
 
Philippe Cassier
Honoraria - Merck; Pierre Fabre; SERVIER
Consulting or Advisory Role - Boehringer Ingelheim; Brenus Pharma; Bristol-Myers Squibb/Celgene; Grey Wolf Therapeutics; MabQuest; OSE Immunotherapeutics; Scenic Biotech; START
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); Alligator Bioscience (Inst); Amgen (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Daiichi Sankyo/UCB Japan (Inst); Debiopharm Group (Inst); Dragonfly Therapeutics (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Grey Wolf Therapeutics (Inst); Incyte (Inst); Innate Pharma (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Kazia Therapeutics (Inst); Kinnate Biopharma (Inst); Lilly (Inst); Loxo (Inst); MABQUEST (Inst); Merck Sharp & Dohme (Inst); Molecular Partners (Inst); Novartis (Inst); OnKure (Inst); OSE Immunotherapeutics (Inst); Pierre Fabre (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Roche/Genentech (Inst); Sotio (Inst); Taiho Pharmaceutical (Inst); Tango Therapeutics (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Novartis; OSE Immunotherapeutics; Pierre Fabre
(OPTIONAL) Uncompensated Relationships - ReACT Therapeutics
 
Stefan Symeonides
Consulting or Advisory Role - Duke Street Bio (Inst); Ellipses Pharma (Inst); Exscientia (Inst); Grey Wolf Therapeutics (Inst); MSD (Inst); Roche (Inst)
Research Funding - BiolineRx (Inst); BioNTech (Inst); Boston Pharmaceuticals (Inst); Corbus Pharmaceuticals; GlaxoSmithKline; Grey Wolf Therapeutics; Incyte (Inst); Medannex (Inst); Merck Sharp & Dohme (Inst); Nouscom (Inst); Nucana (Inst); Nuvectis Pharma; Pfizer; Roche/Genentech (Inst); Sapience Therapeutics (Inst); Scancell (Inst); Sierra Oncology (Inst); Verastem (Inst)
 
Natalie Hyland
Employment - Grey Wolf Therapeutics
Stock and Other Ownership Interests - Grey Wolf Therapeutics
 
Cheryl McAlpine
Employment - Grey Wolf Therapeutics
Stock and Other Ownership Interests - Grey Wolf Therapeutics
 
Tanya Palmer
Employment - Grey Wolf Therapeutics
Stock and Other Ownership Interests - Grey Wolf Therapeutics
Consulting or Advisory Role - Grey Wolf Therapeutics
 
Thomas Lillie
Employment - Grey Wolf Therapeutics Ltd
Leadership - Grey Wolf Therapeutics Ltd
Stock and Other Ownership Interests - Grey Wolf Therapeutics; PsiOxus Therapeutics